Table 1 Inclusion and exclusion criteria

From: The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting

Main inclusion criteria

Main exclusion criteria

All of the following:

Age between 18 and 75 years

A WHO 2008-defined ET diagnosis

Ongoing aspirin 100 mg daily since at least 3 months, according to the judgment of the referring hematologist

 The patient understands and voluntarily signs an informed consent

Any of the following:

 Platelet count > 1 000 000/μl on three occasions over the 2 months before enrollment

 Diabetes according to American Diabetes Association criteria

 Creatinine level > 1.5× upper limit of normal

 Liver disease defined as AST and/or ALT values > 3× upper limit of normal

 Active gastrointestinal disease

 Obesity (BMI > 30 kg/m2)

 Smoking habits (>5 cigarettes/day)

 History of major bleeding

History of cancer in the previous 3 years, except for treated early-stage squamous or basal cell skin carcinomas

 Pregnancy or lactation

 Use of nonsteroidal anti-inflammatory drugs >3 times/week

 Use of antiplatelet agents other than aspirin 100 mg

Use of oral anticoagulants including anti-vitamin K, anti-Xa, or -IIa agents

 Use of heparins or fondaparinux

 Chronic use of steroids (prednisone > 5 mg/day or equivalent)

Back to article page